IMCR · NASDAQ · Biotechnology

Immunocore (ADR) (IMCR)

Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.

$31.52
vs last close−0.90 (−2.76%)